첫 페이지 News 본문

On November 28th, BeiGene announced that its independently developed anti-PD-1 antibody Baize'an (Trastuzumab Injection) and BTK inhibitor Baiyueze (Zebutinib Capsules) have been added to the new version of the national medical insurance drug list with three new indications and one additional indication, respectively; The cooperative introduction of product Baituowei (injectable goserelin microspheres) has added an indication and been included in the national medical insurance drug catalog. Kailuos (injectable carfilzomide) has successfully renewed its contract.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

海角七号 注册会员
  • Follow

    0

  • Following

    1

  • Articles

    29